Abstract 1907P
Background
ICB can achieve durable benefit in aRCC, but reliable biomarkers are lacking. Despite ongoing research, current aRCC biomarkers fail across trials.
Methods
We performed a comprehensive biomarker discovery in our in house, real world aRCC transcriptomic dataset of ICB treated patients (anti-CTLA4+anti-PD1 and anti-PD1) with corresponding human leukocyte antigen (HLA) genotypes to characterize antigen presenting features. Using machine learning (ML) as a wrapper, a transcriptomic biomarker set reflecting HLA promiscuity (HLApr) was developed. We studied its impact on outcome in our ICB treated cohort, in external ICB treated aRCC cohorts (IMmotion150/Miao et al/Choueiri et al, Javelin101) and post-nephrectomy patients (TCGA KIRC).
Results
Increased tumor-relevant antigen binding specificity of HLAs over other antigens (low HLApr) correlated with improved overall survival (OS) after ICB (hazard ratio (HR) 0,4; 95% CI 0,21-0,75, p=0,004, n=98), independent of IMDC risk groups on multivariable analysis, and with a trend towards longer progression free survival (PFS) (HR 0,69, 95%CI 0,38-1,27, p=0,2). Analysis of immunopeptidome-derived and experimentally-validated HLA allele-antigen pairs confirmed that HLA alleles with lower HLApr and correlated with OS upon ICB preferentially bound neo-antigens. A ML based signature was developed that cross-linked transcriptomic footprints with low HLApr, which correlated with OS in our ICB treated cohort (HR 0,56, 95%CI 0,34-0,94, p=0,03), and trended towards correlation with PFS (HR 0,66, 95%CI 0,42-1,03, p=0,07). The signature correlated with PFS in external ICB treated cohorts Javelin101 (HR 0,73, 95%CI 0,54-0,99, p=0,04, n=354) and IMmotion150/Miao et al/Choueiri et al (HR 0,47, 95%CI 0,26-0,86, p=0,015, n=207) and with OS in TCGA KIRC (HR 0,52, 95%CI 0,38-0,71, p<0,001, n=511). In Departmenth tumor immune analyses identified antigen presentation, interferon signalling and myeloid-T cell crosstalk as determinants of ICB responders.
Conclusions
In Departmenth multi-omics analysis revealed critical importance of antigenic myeloid-T cell crosstalk, driven by high neo-antigenicity, to ensure adequate ICB response in aRCC.
Clinical trial identification
S53479/S63833.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
“Kom op tegen Kanker” (Stand up to Cancer), Flemish cancer society. Research Foundation Flanders (FWO). Unrestricted research grants of Pfizer and Ipsen. iBOF grant (VLIR UoS). KU Leuven (C1, C3 grants). Company funding from Boehringer Ingelheim, SOTIO and BMS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23